Previous Statements by AGEN
» Antigenics CEO Discusses Q4 2010 Results - Earnings Call Transcript
» Antigenics CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Antigenics Inc. Q2 2010 Earnings Call Transcript
These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Reference to risks and uncertainties is made in today’s press release and they are disclosed in more detail in our more recent filing – in most recent filings with the U.S. SEC.These statements speak only as of the date of this call and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. When evaluating Agenus’ business and securities, investors should give careful consideration to these risks and uncertainties. As a reminder, this call is being recorded for audio replay. With that, I will now review our financial results for the second quarter and first half of 2011. The company reported net loss attributable to common stockholders of $6 million or $0.05 per share basic and diluted for the second quarter of 2011, compared to a net loss attributable to common stockholders in the second quarter of 2010 of $5.2 million or $0.05 per share basic and diluted. For the six months ended June 30, 2011, the company incurred a net loss attributable to common stockholders of $12.1 million or $0.11 per share basic and diluted, compared with a net loss attributable to common stockholders of $14.2 million or $0.15 per share basic and diluted for the comparable period in 2010. The company’s net cash burn, which is cash used in operating activities plus capital expenditures and dividend payments for the second quarter of 2011 and 2010 was $4.2 million and $3.5 million, respectively. The 2011 net cash burn figure primarily reflects the company’s efforts to support the Prophage Series of cancer vaccines. Cash, cash equivalents and short-term investments were $12 million as of June 30, 2011. This concludes the financial portion of the call. Garo will now provide a brief corporate update.
Garo ArmenThank you, Shalini. I would like to begin this call by highlighting the fact that many of the clinical programs that have been under development for several years by us and by our partners are making significant progress and continue to mature. This is a very exciting time for the company as we could hit as many as eight upcoming milestone events reported in the second half of this year through 2012 and all of which obviously could be great value to us and to our shareholders. We are excited to be participating in the advancing Immunotherapy field with several steps the potential success in many vaccine candidates utilizing our platform and technology in the advantage of clinics and several are getting very close to potential commercialization. It is important also note that beyond our saponin platform of QS-21 Stimulon adjuvant and our recombinant common series platform, which is represented with HerpV for the treatment of genital herpes. Agenus is well-positioned with its Prophage series of vaccines prevent it from recent advances in the field of cancer immunology and cancer vaccines. The FDA approval for Prophage and ponezumab which represents very important immune system modifying drugs, validate the fact that in addition to preventing disease, immune based drugs can be successfully used in the treatment of cancer. To start, I would like to now give you a brief overview of QS-21 Stimulon adjuvant, which is a part of our saponin platform. Adjuvants are an essential part of an effective vaccine as it enhance the ability of a vaccine to elicit strong and durable immune responses. Key licensees of QS-21 include GlaxoSmithKline and JANSSEN Alzheimer Immunotherapy, which is a division of J&J. The programs under development by our partners are advancing and data from Phase 3 clinical trials of three vaccine candidates for malaria and [MAGE IIIA] in non-small cell lung cancer and melanoma are anticipated to be released in the second half of this year, as well as during 2012. A Phase 3 vaccine program for shingles continues to rapidly advance in the clinic. Read the rest of this transcript for free on seekingalpha.com